drugset / Trial / NCT04371666
Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in participants with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).
Timeline
- Start
- 2020-08-10
- Primary completion
- 2023-02-13
- Completion
- 2023-08-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamrevlumab | Monoclonal antibody | 35 mg/kg | Intravenous |
| Background | Deflazacort | Other / unclassified | — | Oral |